Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB803 for corneal abrasions in DEB
NCT07016750Phase 3Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Nanoparticles, Implantable Devices
- Countries
- 1
01
Overview
A Phase 3 trial of KB803 in dystrophic epidermolysis bullosa (DEB), sponsored by Krystal Biotech, Inc.. Started Jun 2025; status: recruiting.
02
Drugs
KB803
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT07016750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016750.